Cmin (EU) [Surveys]

posted by d_labes  – Berlin, Germany, 2010-01-04 11:45 (5644 d 16:15 ago) – Posting: # 4555
Views: 14,130

Dear Helmut,

Ad 1)

❝ How do you define Cmin in steady state?

1.a) as standard, 1.a) or 1.c) as option
Ad 1e)

❝ Additional question: your rationale for either of the above

for 1.a) Common sense (what is a minimum?), ease of calculation and consistency (same value used for other parameters like swing or PTF)
for 1.a) or 1.c) Sponsor's wish

Ad 2)

❝ Do you only report values for the formulations (geometric mean, sd) ...

It depends (not at least on sponsor's wish :-D ).

Ad 3)

❝ If the latter, do you use the metric in a confirmatory analysis (e.g., state an acceptance range)? ...

See ad 2)
Never used 3.c)
Acceptance range usually 0.8-1.25, but also widening.

Ad 4)

❝ Did you have any problems with your approach?

No problems so far for the definition of Cmin (regardless of which).
Usual problems in case of widening acceptance range:
"The applicant should justify the widening ... :blahblah: ".

Ad 5)

❝ Do you see a change in point of views by European regulators ...

None due to rare use of steady state studies.

Ad 6)

❝ Do you consider widening of the acceptance range in a replicate design in steady state (i.e., TTRR-RRTT)

         ^^^^  :ponder:
See ad 5)


Best wishes for the New Year
Regards

D. Labes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
41 visitors (0 registered, 41 guests [including 9 identified bots]).
Forum time: 05:00 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5